论文部分内容阅读
目的探讨FOLFOX4方案系统性化疗治疗进展期肝细胞癌(HCC)的疗效。方法回顾性分析2007年7月至2013年7月中山大学附属第一医院采用FOLFOX4方案系统性化疗治疗的22例进展期HCC病人的临床资料。每2周为1个疗程,最多8个疗程;每3个疗程及治疗结束后评估肿瘤情况。结果 22例病人共接受85个疗程的治疗,平均(3.7±2.0)个疗程。无治愈,5例为部分有效,5例为疾病静止,12例为疾病恶化,客观缓解率为22.7%(5/22),疾病控制率为45.4%(10/22),无严重不良反应发生。随访时间为2~34(8.5±1.9)个月,1年存活率为12.1%,中位生存期为5.8个月。在获得疾病控制的10例病人中,中位生存期为9.5个月。结论 FOLFOX4方案系统性化疗对部分进展期HCC病人有效,是可选择的一种治疗手段。
Objective To investigate the efficacy of systemic chemotherapy with FOLFOX4 regimen in the treatment of advanced hepatocellular carcinoma (HCC). Methods The clinical data of 22 patients with advanced HCC who underwent systematic chemotherapy with FOLFOX4 regimen in the First Affiliated Hospital of Sun Yat-sen University from July 2007 to July 2013 were retrospectively analyzed. Every 2 weeks for a course of treatment, up to 8 courses; every 3 courses and assessment of tumor after treatment. Results 22 patients received a total of 85 courses of treatment, with an average of (3.7 ± 2.0) courses. 5 were partially effective, 5 were still, 12 were worsening, objective response rate was 22.7% (5/22), disease control rate was 45.4% (10/22), no serious adverse reactions occurred . The follow-up time ranged from 2 to 34 (8.5 ± 1.9) months, the 1-year survival rate was 12.1%, and the median survival time was 5.8 months. Among the 10 patients with disease control, the median survival was 9.5 months. Conclusion FOLFOX4 regimen systemic chemotherapy is effective for some advanced HCC patients and is an alternative treatment.